Evidence map›Paper›PMID 25961062›Full record

ArticleJournal of immunology research2015

IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

Fabio Morandi, Michela Croce, Giuliana Cangemi, Sebastiano Barco, Valentina Rigo, Barbara Carlini, Loredana Amoroso, Vito Pistoia, Silvano Ferrini, Maria Valeria Corrias

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. CAR T Cell Therapy for Neuroblastoma.Frontiers in immunology · 2018
    Review
  9. Article
  10. Review
  11. Article
  12. CD4Oncoimmunology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fabio MorandiLaboratorio di Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.ORCID 0000-0002-2849-7595
Michela CroceLaboratorio di Bioterapia, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy.
Giuliana CangemiLaboratorio di Patologica Clinica IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.
Sebastiano BarcoLaboratorio di Patologica Clinica IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.ORCID 0000-0002-1148-427X
Valentina RigoLaboratorio di Bioterapia, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy.
Barbara CarliniLaboratorio di Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.
Loredana AmorosoU.O. Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.
Vito PistoiaLaboratorio di Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.ORCID 0000-0003-0528-9563
Silvano FerriniLaboratorio di Bioterapia, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy.
Maria Valeria CorriasLaboratorio di Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy.ORCID 0000-0002-7316-0772
Istituto Giannina Gaslini · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of the immunosuppressive molecules IL-10 and arginase 1 (ARG-1), and of FOXP3 and CD163, as markers of regulatory T cells (Treg) and macrophages, respectively, was evaluated in bone marrow (BM) and peripheral blood (PB) samples collected at diagnosis from patients with metastatic neuroblastoma (NB). IL-10 and ARG-1 plasma concentrations were measured and the association of each parameter with patients' outcome was tested. The percentages of immunosuppressive Treg and type-1 regulatory (Tr1) cells were also determined. In both BM and PB samples, IL-10 mRNA expression was higher in metastatic NB patients than in controls. IL-10 plasma concentration was higher in patients with NB regardless of stage. Neither IL-10 expression nor IL-10 plasma concentration significantly associated with patient survival. In PB samples from metastatic NB patients, ARG-1 and CD163 expression was higher than in controls but their expression did not associate with survival. Moreover, ARG-1 plasma concentration was lower than in controls, and no association with patient outcome was found. Finally, in metastatic NB patients, the percentage of circulating Treg was higher than in controls, whereas that of Tr1 cells was lower. In conclusion, although IL-10 concentration and Treg percentage were increased, their contribution to the natural history of metastatic NB appears uncertain.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticArginaseBiomarkers, TumorBone MarrowCD163 AntigenChildChild, PreschoolForkhead Transcription FactorsHumansInfantInterleukin-10Lymphocyte CountMacrophagesNeoplastic Cells, CirculatingNeuroblastomaAntigens, CDAntigens, Differentiation, MyelomonocyticARG1 protein, humanArginaseBiomarkers, TumorCD163 AntigenForkhead Transcription FactorsFOXP3 protein, humanIL10 protein, humanInterleukin-10Receptors, Cell SurfaceRNA, Messenger

Identifiers

PMID25961062
PMCPMC4417583
OpenAlexW2074233514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.